Immune therapy trial for deadly childhood brain cancer shows early promise

This early-stage trial tested a new immune cell therapy for children with a rare and aggressive brain stem cancer called DIPG. Eleven children received either chemotherapy plus radiotherapy or radiotherapy alone, followed by infusions of specially trained immune cells and a vaccine. The main goals were to see if the treatment was safe and to find the best dose. The study was stopped early, but it aimed to boost the body's own immune system to fight the tumor.